This study is in progress, not accepting new patients
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic LeukemiaCLLRelapsed or Refractorypreviously treatedLeukemiaLeukemia, LymphoidLeukemia, Lymphocytic, Chronic, B-CellRituximabLenalidomideRevlimidRevlimid + Rituximab
Lead Scientist at UCSD
- Thomas Kipps
Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.